Sage Therapeutics Stock Soars 34.93% on Supernus Acquisition Bid

On June 16, 2025, Sage Therapeutics' stock surged by 34.93% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Supernus Pharmaceuticals has announced its intention to acquire Sage Therapeutics, Inc. The proposed acquisition is expected to accelerate mid- to long-term revenue and cash flow growth for Supernus, further diversifying its revenue base and strengthening its position in the pharmaceutical industry.

Under the terms of the agreement, Supernus will commence a tender offer to acquire all outstanding shares of Sage Therapeutics for a purchase price of $8.50 in cash for each share, with an additional $3.50 per share in cash if certain milestones are achieved. This acquisition is seen as a strategic move by Supernus to enhance its portfolio and expand its market reach.